Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'

 
• By Anju Ghangurde
  
Pros & Cons
GLENMARK HAS DISCONTINUED DEVELOPMENT OF CERTAIN COMPLEX GENERICS
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from India

More from Focus On Asia